Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein. Days after UCB reported the…

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 million upfront to help bypass…

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. The life…

Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas including drug…

After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with…

For the end of this year, Fierce Biotech is taking the opportunity to reflect on trends emerging from 2024’s reporting.…

Ring Therapeutics, a Flagship Pioneering-backed biotech developing new viral vectors for gene therapy delivery, has cut its staff by just…

Freshly public BioAge Labs has secured a multi-year partnership with Novartis that focuses on age-related diseases and includes the possibility…

Pruritus drug developer Cara Therapeutics kicked off the year halving its headcount, and the biotech has now found a new…

Merck & Co. has added a second GLP-1 candidate to its pipeline, paying China’s Hansoh Pharma $112 million upfront for…